Listed

Arbutus Biopharma Corp: Form 10-Q for the period ended Jun 30, 2017

Filed with the SEC on Aug 3, 2017 and accepted by EDGAR at Aug 3, 2017, 17:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-04-01 to 2017-06-30$1.0mus-gaap:Revenues
Revenue6 months2017-01-01 to 2017-06-30$1.3mus-gaap:Revenues
Research and development3 months2017-04-01 to 2017-06-30$15.4mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2017-01-01 to 2017-06-30$29.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-04-01 to 2017-06-30−$19.5mus-gaap:OperatingIncomeLoss
Operating income6 months2017-01-01 to 2017-06-30−$37.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-04-01 to 2017-06-30$68.0kus-gaap:InterestExpense
Interest expense6 months2017-01-01 to 2017-06-30$110.0kus-gaap:InterestExpense
Income tax3 months2017-04-01 to 2017-06-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2017-01-01 to 2017-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-04-01 to 2017-06-30−$18.3mus-gaap:NetIncomeLoss
Net income6 months2017-01-01 to 2017-06-30−$36.9mus-gaap:NetIncomeLoss
Operating cash flow3 months2017-04-01 to 2017-06-30−$5.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Operating cash flow6 months2017-01-01 to 2017-06-30−$22.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2017-04-01 to 2017-06-30$3.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Capital expenditure6 months2017-01-01 to 2017-06-30$6.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-06-30$24.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-06-30$105.9mus-gaap:AssetsCurrent
Total assetsAt period end2017-06-30$255.1mus-gaap:Assets
Current liabilitiesAt period end2017-06-30$11.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-06-30$79.3mus-gaap:Liabilities
Shareholders' equityAt period end2017-06-30$175.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-17-008044. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.